This site is intended for Healthcare Professionals only.

Novartis scraps UK heart attack prevention trial

Date:

Share post:

Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.

A spokesperson said that among the factors influencing the decision, the coronavirus pandemic had made it difficult to make progress on the trial.

Under the ORION-17 trial, planned to involve 40,000 patients, Novartis was trying to show that its Leqvio drug could prevent the first occurrence of major cardiovascular health problems in high-cholesterol patients, part of a broader collaboration with the British health system.

“After careful evaluation, we have decided not to move forward with ORION-17,” the Swiss drugmaker said in an emailed statement on Wednesday. “We continue to have very high ambitions for Leqvio.”

The drug is approved to prevent renewed cardiovascular crises like a heart attack or stroke in people who have already suffered one, known as secondary prevention.

Novartis said it would pursue a different global trial with 14,000 volunteers to show Leqvio’s potential in primary prevention in people at high risk of suffering a first cardiovascular event.

Leqvio, a twice-a-year injection, has had a slow ramp-up phase because cardiologists need to be persuaded to change their billing routines, but analysts have predicted a more than $2 billion sales opportunity from 2025. It would be among the company’s biggest growth drivers during that time.

Credit Suisse analysts said the withdrawal likely “reflects slow progress in initial UK roll out to (general practitioners) in secondary prevention”.

In 2021, Novartis said it had agreed a deal with Britain’s healthcare service provider over the use of Leqvio, after the country’s healthcare cost agency NICE approved the medicine.

The NHS said its wider “population health agreement” with Novartis, which covers secondary prevention, remains in place, adding it “is a pioneering approach to improving treatment for eligible patients with cardiovascular disease across the country.”

The Financial Times first reported that the trial would end.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

How pharmacists can help children and young people with asthma: 2024 AskAboutAsthma campaign highlights

The 2024 #AskAboutAsthma campaign calls on pharmacists to take an active role in improving asthma management and outcomes...

Huxley Europe relaunches HuxQ10 Capsules with triple certification

The relaunch underscores Huxley Europe's commitment to health and welfare, offering specially developed formulas for users with dietary...

Alastair Buxton outlines vision for Community Pharmacy at Westminster Health Forum

Alastair Buxton, Director of NHS Services at CPE, outlines critical issues and solutions at the Westminster Health Forum,...

Food prices remain UK consumers’ top concern, FSA report finds

Consumers worried about food affordability were more likely to take food safety risks to save money The Food...